Compare FAF & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FAF | KRYS |
|---|---|---|
| Founded | 1889 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.8B |
| IPO Year | 2009 | 2017 |
| Metric | FAF | KRYS |
|---|---|---|
| Price | $68.19 | $298.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $82.50 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 748.1K | 273.5K |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | ★ 376.19 | 128.00 |
| EPS | 1.21 | ★ 1.83 |
| Revenue | ★ $7,452,200,000.00 | $389,130,000.00 |
| Revenue This Year | $7.85 | $38.74 |
| Revenue Next Year | $5.57 | $32.53 |
| P/E Ratio | ★ $55.99 | $166.58 |
| Revenue Growth | 21.61 | ★ 33.94 |
| 52 Week Low | $53.95 | $123.03 |
| 52 Week High | $71.47 | $319.48 |
| Indicator | FAF | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 55.98 |
| Support Level | $64.27 | $253.89 |
| Resistance Level | $71.35 | $319.48 |
| Average True Range (ATR) | 1.74 | 11.79 |
| MACD | -0.30 | -0.87 |
| Stochastic Oscillator | 37.75 | 46.86 |
First American Financial Corp is engaged in the business of providing title insurance, settlement services, and other financial services and risk solutions. The group's reportable segments are: Title insurance and services, Home warranty, and Corporate. Maximum revenue is generated from the Title insurance and services segment, which provides title insurance, closing, escrow, and related services domestically and internationally in connection with residential and commercial real estate transactions. This segment also provides solutions to mitigate risk and facilitate real estate transactions, along with offering banking, trust, warehouse lending, mortgage subservicing and wealth management services. The majority of the group's revenue is generated from escrow fees and insurance premiums.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.